Canadian universities are at the forefront of innovative cannabinoid research, leveraging advanced delivery technologies like QuickStrip to explore new treatments for chronic pain and concussion-related neuroprotection. This collaboration between academia and industry, bolstered by funding from the National Football League (NFL), highlights the growing role of higher education in translating cannabis science into practical therapeutic solutions. With legalization across Canada since 2018, postsecondary institutions have ramped up studies on cannabinoids—naturally occurring compounds in cannabis plants such as cannabidiol (CBD) and tetrahydrocannabinol (THC)—focusing on their potential in sports medicine and beyond.

The surge in research reflects broader trends: cannabis use among Canadians rose 40% from 2017 to 2023, reaching nearly 29% prevalence, with young adults aged 15-35 leading the way. Universities are key players, conducting clinical trials, pharmacokinetic analyses, and physiological studies to ensure safe, effective applications.

Understanding QuickStrip™ Technology in Cannabinoid Delivery

QuickStrip™, developed by Burlington, Ontario-based biotech firm Rapid Dose Therapeutics (RDT), is an oral thin film strip designed for sublingual or buccal absorption. Placed under the tongue or against the cheek, the micronized film dissolves rapidly—often within seconds—releasing cannabinoids directly into the bloodstream via mucous membranes. This bypasses first-pass metabolism in the liver, which degrades up to 90% of orally ingested CBD or THC when swallowed in capsules or edibles.

The process works step-by-step: 1) The strip's polymer matrix holds precisely dosed active ingredients; 2) Saliva hydrates it, triggering dissolution; 3) Cannabinoids permeate the oral mucosa for near-intravenous speed onset (5-15 minutes vs. 30-90 for edibles); 4) Bioavailability reaches 30-50%, compared to 6-20% for traditional oral forms. This makes QuickStrip ideal for acute needs like pain relief or neuroprotection.

• Rapid onset: Mimics injection pharmacokinetics without needles.
• Precision dosing: Each strip delivers exact micrograms, reducing variability.
• Discreet use: No water needed, portable for athletes or patients.

Canadian universities have validated this through collaborations, including NSERC-funded work at McMaster University on enhanced solubility via cyclodextrin complexes.

University of Regina Leads NFL-Funded Concussion Studies

Dr. J. Patrick Neary, professor in the Faculty of Kinesiology and Health Studies at the University of Regina, spearheads the NFL-funded project "Naturally Produced Cannabinoids for Pain Management and Neuroprotection from Concussion and Participation in Contact Sports." Awarded over $500,000 USD in 2022, with ongoing support, the research examines how CBD-dominant formulations mitigate inflammation and oxidative stress post-concussion.

Neary's team uses advanced neuroimaging and physiological monitoring to track cerebral blood flow, cognitive function, and biomarker changes. A 2024 publication in Pharmacology Research & Perspectives detailed dose-response effects of CBD, showing reduced pro-inflammatory cytokines at 20-50 mg doses. ClinicalTrials.gov lists NCT06204003, testing daily CBD safety in chronic pain patients alongside concussion models.

This work addresses Canada's rising concussion rates in sports—over 200,000 annually—with cannabinoids offering non-opioid alternatives amid the opioid crisis.Explore research assistant roles in kinesiology.

University of Saskatchewan's Pharmacokinetic Expertise

Dr. Jane Alcorn, Dean of the College of Pharmacy and Nutrition at the University of Saskatchewan, leads the bioavailability arm. Launched Q2 2024, the Health Canada-approved trial compares CBD QuickStrip to oral powder in healthy adults, measuring plasma levels, half-life, and metabolites over 24 hours. As of February 2026, over 60% of data is analyzed, confirming faster peak concentrations with strips.

Alcorn's prior veterinary and human PK studies underscore cannabinoids' variability due to food effects and genetics. QuickStrip minimizes these, potentially boosting efficacy by 3-5x. Stability tests ensure shelf-life under varying conditions, vital for commercial scaling.View trial details.

• Peak plasma: QuickStrip at 30 min vs. 120 min for capsules.
• AUC (exposure): 35% higher.
• No psychoactivity: Pure CBD focus.

University of British Columbia's Multidisciplinary Contributions

UBC Okanagan's team, including neurophysiologists and psychologists, integrates cerebrovascular assessments. Their input refines protocols for contact sports simulations, using fMRI to observe cannabinoid modulation of blood-brain barrier integrity post-impact.

This tri-university effort exemplifies Canada's ecosystem: over 50 universities conduct cannabis studies, funded by CIHR, NSERC, and industry. Stats show 52% of postsecondary students report past-year use, driving harm reduction research.

Historical Collaborations: McMaster University's Role

McMaster's School of Biomedical Engineering partnered with RDT on NSERC grants since 2020, optimizing QuickStrip for vaccines and drugs. A 2024 study incorporated loratadine-cyclodextrin for 4x solubility gains, paving the way for cannabinoid formulations. This foundational work supports current trials.

McMaster's innovations align with Canada's $5B+ cannabis R&D sector, projected to grow 15% annually through 2030.

Regulatory Landscape and Health Canada Oversight

Health Canada rigorously reviews trials like these under the Special Access Program (SAP) and Cannabis Regulations. QuickStrip products received approvals for medical cannabis in Brazil (ANVISA, 2026), signaling global potential. Canadian pilots, including opioid harm reduction with First Nations, used QuickStrip for precise dosing.

Universities ensure GCP compliance, with ethics boards prioritizing athlete safety. Post-legalization, adverse events dropped 20%, per BMJ Open.

Implications for Pain Management and Sports Health

Chronic pain affects 20% of Canadians; opioids claim 20 lives daily. Cannabinoids via QuickStrip offer alternatives: Neary's data shows 30% pain reduction, improved sleep. For concussions—common in hockey, football—neuroprotection could shorten recovery by weeks.

• Athletes: Faster relief without impairment.
• Patients: Elderly, remote communities benefit from no-swallow format.
• Economy: Reduced healthcare costs ($10B/year pain-related).

Challenges and Future Outlook

Challenges include standardization, long-term safety, and stigma. Universities address via longitudinal cohorts. Future: Phase III trials 2027, pharma partnerships. With 133 cannabis research grants in 2025, Canada leads globally.

QuickStrip could revolutionize delivery, spawning jobs in formulation science. Check research positions.

Photo by Hermes Rivera on Unsplash

Careers in Cannabinoid Research at Canadian Universities

Higher ed drives innovation: roles in PK labs, clinical coordination abound. Salaries average $80K-$120K for postdocs. Rate professors like Neary. Build your CV.

Explore higher ed jobs, university jobs, and career advice.